TABLE 1.
Characteristics of human subjects used in this study.
| Control | AsymAD | AD | PD | |
| (n = 12) | (n = 8) | (n = 12) | (n = 12) | |
| Age at Death, mean years (SD) | 76.0 (10.5) | 82.5 (9.7) | 76.4 (7.4) | 75.1 (6.0) |
| Disease Duration, mean years (SD) | 11.1 (4.0) | 17.5 (9.6) | ||
| Sex, n (%) | ||||
| Male | 6 (50.0) | 5 (62.5) | 8 (66.7) | 9 (75.0) |
| Female | 6 (50.0) | 3 (37.5) | 4 (33.3) | 3 (25.0) |
| Race, n (%) | ||||
| White | 9 (75.0) | 8 (100.0) | 12 (100.0) | 12 (100.0) |
| Black | 2 (16.7) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Hispanic | 1 (8.3) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| PMI, mean hrs (SD) | 7.3 (3.9) | 17.5 (9.6) | 9.5 (8.2) | 12.9 (7.6) |
| Amyloid & Tau Burden | ||||
| CERAD Score | 0.2 (0.4) | 2.8 (0.5) | 3.0 (0.0) | 0.2 (0.4) |
| Braak Score | 1.6 (0.9) | 3.0 (1.2) | 5.9 (0.3) | 2.2 (1.3) |
| ABC Score | 0.5 (0.5) | 1.8 (0.5) | 3.0 (0.0) | 0.4 (0.5) |
| DLB Neocortex Score, (SD) | 0.5 (0.5) | |||
| ApoE Status, n (%) | ||||
| APOE2/2 | 0 (0.0) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| APOE2/3 | 0 (0.0) | 1 (12.5) | 1 (8.3) | 6 (50.0) |
| APOE2/4 | 0 (0.0) | 1 (12.5) | 0 (0.0) | 0 (0.0) |
| APOE3/3 | 12 (100.0) | 3 (37.5) | 2 (16.7) | 4 (33.3) |
| APOE3/4 | 0 (0.0) | 2 (25.0) | 6 (50.0) | 2 (16.7) |
| APOE4/4 | 0 (0.0) | 1 (12.5) | 3 (25.0) | 0 (0.0) |
AsymAD, Asymptomatic Alzheimer’s disease; AD, Alzheimer’s disease; PD, Parkinson’s disease; PMI. Post-Mortem Interval; CERAD, Consortium to Establish a Registry for Alzheimer’s disease; ABC: Amyloid/Braak/CERAD aggregate score (none = 0, low = 1, intermediate = 2, high = 3); SD, Standard Deviation.